Meta-analysisindependent cross-checkfull text checked★ key study I-ODD-113 in-depth review
Pooled trials hint at slightly more pancreatitis with GLP-1 drugs
Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Overview
Wen J et al.. Endocrinol Diabetes Metab 2025 · PMID 40988099 · DOI 10.1002/edm2.70113
RR 1.44 overall, but not significant in subgroups; events rare.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Assess pancreatitis and pancreatic cancer in GLP-1 RA trials.
- How was the study done?
Meta-analysis of 62 RCTs.
- How many people, animals or samples were studied?
66,232 patients.
- What was actually found?
Small overall increase in pancreatitis; no overall increase in pancreatic cancer.
- How large was the observed effect?
RR 1.44 (1.09-1.89).
- What do the results mean in everyday life?
If there is an extra risk, it is small; severe abdominal pain should be checked.
- What are the study's limitations?
Fixed-effect model, mixed definitions, short trials.
- What does it say about Elawady's specific claim?
Partly supports 'can trigger pancreatitis'; no support for cysts.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That GLP-1 RAs cause pancreatic cysts.
Scientific in-depth review
1. Full reference
- Authors
- Wen J et al.
- Journal
- Endocrinol Diabetes Metab
- Year
- 2025
- Identifier
- PMID 40988099 DOI 10.1002/edm2.70113
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
Authors declare no conflicts; no funding reported.
2. Research question
Do GLP-1 RAs increase pancreatitis or pancreatic cancer in RCTs?
3. Study design and population
- Study design
- Meta-analysis – Systematic review and fixed-effect meta-analysis of RCTs
- Population
Patients in GLP-1 RA RCTs (any age)
- Country
International
- Period
Searches not dated in abstract; published 2025
- Sample size
62 RCTs, 66,232 patients; mean follow-up 43.5 weeks
- Inclusion and exclusion criteria
RCTs of GLP-1 RAs reporting pancreatitis/pancreatic cancer; head-to-head GLP-1 RA comparisons eligible; minimum follow-up 1 week
4. Methods and endpoints
- Exposure / intervention
GLP-1 RAs (dulaglutide, exenatide, liraglutide, semaglutide, beinaglutide, retatrutide, tirzepatide)
- Comparator
Placebo or active comparators
- Endpoints
Acute pancreatitis; pancreatic cancer (exploratory)
- Statistical methods
Fixed-effect RR (RevMan); subgroup by background medication
5. Actual results
- Results
Pancreatitis RR 1.44 (1.09-1.89, p=0.009); with background medication RR 1.28 (0.87-1.87); without RR 1.37 (0.91-2.05). Pancreatic cancer RR 1.30 (0.86-1.97); with background medication 1.85 (1.05-3.26); without 0.81 (0.43-1.55). Many trials had zero events in both arms.
- Absolute risks
Not reported as pooled absolute risk; individual agents up to 0.35-0.56% pancreatitis events in arms with the most events.
- Authors' conclusion
GLP-1 RAs carry a slightly increased risk of pancreatitis, not significant when stratified by background medication; difference likely minimal given many zero-event trials.
6. Strengths
- Includes newer agents (tirzepatide, retatrutide)
- RCT-only
7. Weaknesses
- Fixed-effect model despite clinical heterogeneity
- Inconsistent pancreatitis definitions
- Head-to-head GLP-1 RA comparisons pooled with placebo comparisons
- Short mean follow-up
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Fixed-effect pooling and outcome-definition heterogeneity; authors acknowledge low I2 may reflect sparse events.
9. Assessment of the statistical interpretation
CIs log-symmetric (stats/C-ODD-04.py). Significant pooled estimate with non-significant strata reflects reduced power. Contrasts with blinded outcome-trial meta-analyses (I-ODD-11, I-ODD-112) that adjudicated pancreatitis and found no increase.
10. Relevance to the specific claim
The strongest recent RCT-based support for a small pancreatitis increase with GLP-1 RAs; says nothing about cysts.
11. Independent contrary findings
Storgaard 2017 (I-ODD-11), Sattar 2021 (I-ODD-112), LEADER (I-ODD-06).
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
Suggests at most a small relative increase in a rare event; methodologically weaker than outcome-trial analyses.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | moderate |
| Directness | direct |
| Reproducibility | not replicated |
| Consistency with the overall evidence | inconsistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Absolute risk; effect in people with gallstones or prior pancreatitis.
15. Linked fact checks
- Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts. – Studies supporting the claim